• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

3-V Biosciences

edit

3-V Biosciences is a privately held biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases.

3-V Biosciences was founded by The Column Group (TCG) and Kleiner Perkins Caulfield & Byers (KPCB) in March 2007. In April 2007, the original laboratory was opened in Zürich, Switzerland in close proximity to the company’s founders at the ETH (Swiss Federal Institute of Technology) and the University of Zürich. Host pathway screening began in November 2007 and continues today.

Recent Milestones

edit

• 
  3-V Biosciences received $20M in Venture Round funding. (1/5/12)
  Posted 1/5/12 at 7:50pm via finsmes.com
• 
  3-V Biosciences added George Kemble as Chief Scientific Officer. (8/1/11)
  Posted 3/8/13 at 11:16pm
• 
  3-V Biosciences received $30M in Series B funding. (7/10/09)
  Posted 10/7/09 at 8:19pm via 3vbio.com
• 
  3-V Biosciences added Merdad Parsey as Chief Executive Officer & BOD.
  Posted 3/8/13 at 11:16pm

Videos

Screenshots

edit

Above: 3-V Biosciences
Uploaded: 10/8/09

Sources

1. 3-V Biosciences, Inc. Secures $30 Million in Series B Funding, Welcomes New Members to Board of Directors (3vbio.com) [edit]
2. 3-V Biosciences Closes $20M Financing (finsmes.com) [edit]